Difference between revisions of "Rezvilutamide (SHR-3680)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - " (NCT[0-9]{8})" to " https://clinicaltrials.gov/ct2/show/$1") |
Warner-admin (talk | contribs) m (Warner-admin moved page Rezvilutamide (SHR3680) to Rezvilutamide (SHR-3680) without leaving a redirect) |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Prostate cancer]]=== | ===[[Prostate cancer]]=== | ||
| − | #'''CHART:''' Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1249-1260. Epub 2022 Sep 5. [https://doi.org/10.1016/s1470-2045(22)00507-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36075260/ PubMed] https://clinicaltrials.gov/ | + | #'''CHART:''' Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1249-1260. Epub 2022 Sep 5. [https://doi.org/10.1016/s1470-2045(22)00507-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36075260/ PubMed] [https://clinicaltrials.gov/study/NCT03520478 NCT03520478] |
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' SHR-3680 |
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | [[Category: | + | [[Category:Second-generation nonsteroidal antiandrogens]] |
[[Category:Prostate cancer medications (investigational)]] | [[Category:Prostate cancer medications (investigational)]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
Latest revision as of 12:44, 27 July 2023
Mechanism of action
A nonsteroidal antiandrogen.
Preliminary data
Prostate cancer
- CHART: Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1249-1260. Epub 2022 Sep 5. link to original article PubMed NCT03520478
Also known as
- Code name: SHR-3680